<i>In vitro</i> activity of cefiderocol and sulbactam–durlobactam against carbapenem-resistant <i>Acinetobacter baumannii</i> clinical isolates collected between 2019 and 2024
Cefiderocol and sulbactam-durlobactam exhibited strong <i>in vitro</i> activity against carbapenem-resistant <i>A. baumannii</i> isolates from a single University Hospital and may represent valuable treatment options for patients with limited therapeutic alternatives.
Authors
- Elizabeth Palavecino (ORCID: https://orcid.org/0000-0002-4525-6064)
- Abdullah Kılıç (ORCID: https://orcid.org/0000-0003-0875-6593)
Institutions
- Wake Forest University (US)
Publication Details
- Journal
- Infectious Diseases
- Published
- 2025-12-02
- DOI
- https://doi.org/10.1080/23744235.2025.2597465
- Primary Topic
- Antibiotic Resistance in Bacteria
- Type
- article
- Field-Weighted Citation Impact
- 0.00